Conjugated Via A Specifically-identified Linking Group, Coupling Agent, Or Conjugation Agent Patents (Class 530/391.9)
-
Publication number: 20100173382Abstract: Chimeric and humanized anti-5T4 antibodies and antibody/drug conjugates and methods for preparing and using the same.Type: ApplicationFiled: October 16, 2009Publication date: July 8, 2010Applicant: WyethInventors: Erwin R. Boghaert, Nitin K. Damle, Davinder S. Gill, Kimberly A. Marquette, Lioudmila Tchistiakova, Philip Ross Hamann, Arthur Kunz
-
Publication number: 20100150950Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CD70 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human CD70. In certain embodiments, the antibodies are capable of being internalized into CD70-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD70, as well as methods for treating cancers, such as renal cancer and lymphomas, using an anti-CD7Q antibody of this disclosure.Type: ApplicationFiled: December 13, 2007Publication date: June 17, 2010Applicant: Medarex, Inc.Inventors: Marco A. Coccia, Jonathan A. Terrett, David John King, Chin Pan, Josephine Cardarelli, Mark Yamanaka, Ann Karla Henning
-
Patent number: 7737260Abstract: Disclosed are a protein conjugate with improved in vivo duration and stability and the use thereof. The protein conjugate includes a physiologically active polypeptide, a non-peptide polymer and an immunoglobulin Fc fragment. Since the three components are covalently linked, the protein conjugate has extended in vivo duration and enhanced stability for the physiologically active polypeptide. The protein conjugate maintains the in vivo activity at relatively high levels and remarkably increases the serum half-life for the physiologically active polypeptide, with less risk of inducing undesirable immune responses. Thus, the protein conjugate is useful for developing long-acting formulations of various polypeptide drugs.Type: GrantFiled: November 13, 2004Date of Patent: June 15, 2010Assignee: Hanmi Pharm. Co., LtdInventors: Young Min Kim, Dae Jin Kim, Sung Min Bae, Chang Ki Lim, Se Chang Kwon, Gwan Sun Lee
-
Publication number: 20100136033Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.Type: ApplicationFiled: October 30, 2009Publication date: June 3, 2010Applicant: IMMUNOGEN, INC.Inventors: Sharon Erickson, Ralph Schwall, Mark Sliwkowski, Walter Blattler
-
Publication number: 20100129314Abstract: Linkers for binding drugs to cell binding agents are modified to hydrophilic linkers by incorporating a polyethylene glycol spacer. The potency or the efficacy of the cell-binding agent-drug conjugates is surprisingly enhanced several folds in a variety of cancer cell types, including those expressing a low number of antigens on the cell surface or cancer cells that are resistant to treatment. A method for preparing maytansinoids bearing a thioether moiety and a reactive group which allows the maytansinoid to be linked to a cell-binding agent in essentially a single step is also provided.Type: ApplicationFiled: October 6, 2009Publication date: May 27, 2010Applicant: Immunogen Inc.Inventors: Rajeeva Singh, Yelena Kovtun, Sharon D. Wilhelm, Ravi V.J. Chari
-
Publication number: 20100104589Abstract: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.Type: ApplicationFiled: December 2, 2009Publication date: April 29, 2010Applicant: IMMUNOMEDICS, INC.Inventors: Serengulam V. Govindan, Sung-Ju Moon, David M. Goldenberg
-
Publication number: 20100105877Abstract: The present invention relates to an insulinotropic peptide conjugate having improved in-vivo duration of efficacy and stability, comprising an insulinotropic peptide, a non-peptide polymer and an immunoglobulin Fc region, which are covalently linked to each other, and a use of the same. The insulinotropic peptide conjugate of the present invention has the in-vivo activity which is maintained relatively high, and has remarkably increased blood half-life, and thus it can be desirably employed in the development of long acting formulations of various peptide drugs.Type: ApplicationFiled: January 4, 2008Publication date: April 29, 2010Applicant: HANMI PHARMACEUTICAL CO., LTD.Inventors: Dae Hae Song, Chang Ki Lim, Tae Hun Song, Young Hoon Kim, Se Chang Kwon, Gwan Sun Lee, Sung Youb Jung, In Young Choi
-
Publication number: 20100092496Abstract: The present disclosure provides drug-ligand conjugates that are potent cytotoxins, wherein the drug is linked to the ligand through either a peptidyl, hydrazine, or disulfide linker. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.Type: ApplicationFiled: November 2, 2009Publication date: April 15, 2010Applicant: Medarex, Inc.Inventors: Sharon E. Boyd, Liang Chen, Sanjeev Gangwar, Vincent Guerlavais, Killian Horgan, Zhi-Hong Li, Bilal Sufi
-
Publication number: 20100074910Abstract: The present disclosure provides methods for treating cancer in a patient in need of such treatment, the method includes prequalifying a patient's therapeutic treatment by performing a molecular imaging procedure to the patient using a labeled biomarker specific for a cancer target at the tumor site; and administering a therapeutic effective amount of a compound comprising a targeting agent linked to a chemotherapeutic or a targeting agent linked to an antibody. Embodiments of the present invention also include compounds and compositions for using such methods.Type: ApplicationFiled: June 1, 2009Publication date: March 25, 2010Applicant: Siemens Medical Solutions USA, Inc.Inventors: Hartmuth C. Kolb, Joseph C. Walsh, Kai Chen, Dhanalakshmi Kasi, Umesh B. Gangadharmath, Peter J.H. Scott, Gang Chen, Vani P. Mocharla
-
Publication number: 20100062008Abstract: Drug-Linker-Ligand Conjugates are disclosed in which a Drug is linked to a Ligand via a peptide-based Linker unit. In one embodiment, the Ligand is an Antibody. Drug-Linker compounds and Drug compounds are also disclosed. Methods for treating cancer, an autoimmune disease or an infectious disease using the compounds and compositions of the invention are also disclosed.Type: ApplicationFiled: November 18, 2009Publication date: March 11, 2010Applicant: Seattle Genetics, Inc.Inventors: Peter D. Senter, Svetlana O. Doronina, Brian E. Toki
-
Patent number: 7662936Abstract: Methods to detect, screen, and quantitate biological samples after administration of antibody conjugates, antibody-drug conjugates of Formula I, antibodies, and fragments and metabolites thereof, by affinity separation, chromatography, and mass spectrometry are disclosed. Ab-(L-D)p??I wherein Ab is an antibody; D is a drug moiety; L is a linker covalently attached to Ab, and covalently attached to D; and p is 1, 2, 3, 4, 5, 6, 7, or 8.Type: GrantFiled: April 6, 2005Date of Patent: February 16, 2010Assignee: Genentech, Inc.Inventors: Miryam Kadkhodayan, Emily Mann
-
Publication number: 20100034837Abstract: The present invention relates to conjugates of therapeutically useful anthracyclines with carriers such as polyclonal and monoclonal antibodies, proteins or peptides of natural or synthetic origin; methods for their preparation, pharmaceutical composition containing them and use thereof in treating certain mammalian tumors.Type: ApplicationFiled: July 14, 2009Publication date: February 11, 2010Inventors: Italo Beria, Michele Caruso, John A. Flygare, Vittoria Lupi, Rita Perego, Paul Polakis, Andrew Polson, Matteo Salsa, Susan D. Spencer, Barbara Valsasina
-
Publication number: 20100028370Abstract: The present invention is directed to a methods and compositions for receptor mediated drug delivery, particularly across the blood-brain barrier.Type: ApplicationFiled: July 24, 2009Publication date: February 4, 2010Applicant: RAPTOR PHARMACEUTICAL INC.Inventors: TODD ZANKEL, Christopher M. Starr
-
Publication number: 20100021483Abstract: Chimeric and humanized anti-5T4 antibodies and antibody/drug conjugates and methods for preparing and using the same.Type: ApplicationFiled: July 1, 2009Publication date: January 28, 2010Applicant: WyethInventors: ERWIN R. BOGHAERT, Nitin K. Damle, Davinder S. Gill, Kimberly A. Marquette, Lioudmila Tchistiakova, Philip Ross Hamann, Arthur Kunz
-
Publication number: 20100021379Abstract: The present invention provides antibody conjugates comprising a targeting agent covalently attached to an antibody or fragment thereof. The antibody conjugates of the present invention are particularly useful for imaging a tumor, organ, or tissue and for treating diseases and disorders such as cancer, inflammatory diseases, autoimmune diseases, infectious diseases, and neurological disorders. Kits containing the antibody conjugates described herein find utility in a wide range of applications including, for example, in vivo imaging and immunotherapy.Type: ApplicationFiled: June 28, 2007Publication date: January 28, 2010Applicant: The Regents of the University of CaliforniaInventors: Kit S. Lam, Pappanaicken R. Kumaresan, Amanda Enstrom, Ruiwu Liu
-
Publication number: 20100022615Abstract: Activated cytotoxic compounds are described for attachment to targeting molecules for the treatment of a mammalian disease condition which comprise, an activator, a spacer linker, a linker (e.g., self-immolative), and a cytotoxic drug selected from the group consisting of AMINO-SUBSTITUTED (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES, AMINO-AND-HYDROXY SUBSTITUTED STYRYLSULFONANILIDES, and SUBSTITUTED PHENOXY- AND PHENYLTHIO-STYRYLSULFONE DERIVATIVES. Activated cytotoxic compound attached to a targeting molecule are described wherein the targeting molecule is selected from the group consisting essentially of an antibody, a receptor, a ligand, a cytokine, a hormone, and a signal transduction molecule. The invention is further directed to a method of treatment of disease conditions.Type: ApplicationFiled: September 14, 2007Publication date: January 28, 2010Applicant: Onconova Therapeutics, IncInventors: Glenn Fegley, Stanley C. Bell, Stephen Cosenza, Jodie Duke, Reddy H. Premkumar, Reddy M. V. Ramana
-
Publication number: 20100003267Abstract: The present invention provides VEGF binding peptides. In addition, the invention provides VEGF peptides conjugated to antibodies alone and in conjunction with other anti-angiogenic molecules. Various uses of the peptides and compounds are provided, including methods to treat disorders associated with abnormal angiogenesis.Type: ApplicationFiled: April 29, 2009Publication date: January 7, 2010Inventors: Venkata Ramana Doppalapudi, Jing-Yu Lai, Bin Liu, Dingguo Liu, Joel Desharnais, Abhijit Suresh Bhat, Yanwen Fu, Bryan Douglas Oates, Gang Chen, Curt William Bradshaw
-
Publication number: 20090324621Abstract: Drug-Linker-Ligand Conjugates are disclosed in which a Drug is linked to a Ligand via a peptide-based Linker unit. In one embodiment, the Ligand is an Antibody. Drug-Linker compounds and Drug compounds are also disclosed. Methods for treating cancer, an autoimmune disease or an infectious disease using the compounds and compositions of the invention are also disclosed.Type: ApplicationFiled: March 20, 2009Publication date: December 31, 2009Applicant: Seattle Genetics, Inc.Inventors: Peter D. Senter, Svetlana O. Doronina, Brian E. Toki
-
Publication number: 20090304689Abstract: Methods and compositions for the development of effective cancer therapies using mitotic inhibitors which have limited general toxicity to normal, non-cancerous cells and tissues are provided. The methods and compositions utilize cytotoxic compounds comprised of a cell-binding agent (e.g., antibodies) conjugated to an anti-mitotic compound (e.g., maytansinoids). The invention further provides antibodies which are substantially incapable of inducing antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC), thereby ensuring that the therapeutic effect is mediated primarily by the anti-mitotic component of the cytotoxic compound, rather than by indirect cell killing via ADCC and/or CDC. The antibodies of the invention further are capable of differentiating between polypeptide antigens which are more highly expressed on proliferating cancer cells as compared to proliferating non-cancer cells.Type: ApplicationFiled: February 2, 2009Publication date: December 10, 2009Inventor: Arthur D. Levinson
-
Publication number: 20090297620Abstract: Titanium oxide-antibody conjugated particles are disclosed, which are provided with selective binding ability without loss of dispersibility and catalytic activity by modifying titanium oxide conjugated particles, dispersed in a water-based solvent by a water-soluble polymer, with an antibody via a linker molecule bound without changing the nature of the water-soluble polymer. The present invention is an antitumor agent, comprising titanium oxide-antibody conjugated particles, wherein a linker molecule is bound to the titanium oxide surface of the titanium oxide conjugated particles, dispersed in a water-based solvent by a water-soluble polymer, via at least one functional group selected from a group consisting of a carboxyl group, an amino group, a diol group, a salicylic acid group, and a phosphoric acid group, and wherein the titanium oxide conjugated particles are further modified with an antibody via the linker molecule.Type: ApplicationFiled: April 7, 2009Publication date: December 3, 2009Applicant: Toto Ltd.Inventors: Koki Kanehira, Shuji Sonezaki, Yumi Ogami, Tomomi Nakamura, Toshiaki Banzai
-
Publication number: 20090286964Abstract: The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.Type: ApplicationFiled: August 1, 2008Publication date: November 19, 2009Inventors: Colin Gegg, Fei Xiong, Karen C. Sitney
-
Publication number: 20090280056Abstract: Anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-STEAP-1 antibodies and immunoconjugates thereof are provided.Type: ApplicationFiled: October 26, 2007Publication date: November 12, 2009Inventors: Mark S. Dennis, Bonnee Rubinfeld, Paul Polakis, Aya Jakobovits
-
Publication number: 20090274713Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.Type: ApplicationFiled: April 30, 2009Publication date: November 5, 2009Applicant: IMMUNOGEN INC.Inventors: Ravi V. J. CHARI, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne Charles Widdison
-
Publication number: 20090232833Abstract: The present invention provides polymeric delivery systems including hindered ester moieties. Methods of making the polymeric delivery systems and methods of treating mammals using the same are also disclosed.Type: ApplicationFiled: March 12, 2009Publication date: September 17, 2009Applicant: ENZON PHARMACEUTICALS, INC.Inventor: Hong ZHAO
-
Patent number: 7585491Abstract: The invention relates to therapeutic conjugates with improved ability to target various cancer cells containing a targeting moiety and a therapeutic moiety. The targeting and therapeutic moieties are linked via an acid cleavable linkage that increases therapeutic efficacy of the immunoconjugate.Type: GrantFiled: December 15, 2003Date of Patent: September 8, 2009Assignee: Immunomedics, Inc.Inventor: Serengulam V. Govindan
-
Publication number: 20090220501Abstract: Provided is an immunotoxin including (a) an anti-CD19 antibody lacking an Fc fragment, (b) a modified exotoxin A protein having both Domains II and III, but lacking Domain I, and (c) a peptide linker joining the C-terminal end of the antibody to the N-terminal end of the modified exotoxin A protein. The linker is substantially resistant to extracellular cleavage. The modified exotoxin A protein may be further modified to include a C-terminal KDEL sequence (SEQ ID NO: 6) that promotes transport of the protein to the endoplasmic reticulum of cells that have taken up the immunotoxin. Also provided is an anti-CD19 antibody having enhanced binding activity, antibody-dependent cellular cytotoxicity (ADCC) and methods for using the antibody to treat a disease state associated with B-lineage cells that express CD19. The antibody variable light and variable heavy chains have unique sequences in their J region relative to known anti-CD19 antibody sequences.Type: ApplicationFiled: July 17, 2008Publication date: September 3, 2009Inventors: Georg H. Fey, Matthias Peipp, Michael Schwemmlein, Bruce Wang, Matthias Wabl
-
Publication number: 20090214438Abstract: The present invention relates to methods for the preparation of toxin conjugates that are useful in vaccination and other therapies and diagnostics. In particular, methods are provided that involve a [3+2] cycloaddition between a first reactive unsaturated group on a toxin moiety and a second reactive unsaturated group on a bioactive moiety. Also provided are conjugates that are formed through this conjugation method, pharmaceutical compositions comprising these conjugates, and methods of using these pharmaceutical compositions for the treatment or diagnostic of antigen-related conditions, including tumors and infections.Type: ApplicationFiled: December 18, 2008Publication date: August 27, 2009Applicants: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRSInventors: Ludger JOHANNES, Baldissera GIOVANI, Michel AZOULAY, Jean-Claude FLORENT
-
Publication number: 20090215996Abstract: Crosslinked polymeric materials are described that contain pendant amine capture groups. The amine capture groups include N-sulfonyldicarboximide groups that can react with amine-containing materials by a ring opening reaction. Reaction mixtures used to prepare the crosslinked polymeric materials, articles containing the crosslinked polymeric materials, methods of making articles, and methods of immobilizing an amine-containing material are also described.Type: ApplicationFiled: April 30, 2009Publication date: August 27, 2009Inventors: George G.I. Moore, Rahul R. Shah, Karl E. Benson, Charles M. Leir
-
Publication number: 20090209734Abstract: The present invention provides analogues of duocarmycins that are potent cytotoxins. Also provided are peptidyl and disulfide linkers that are cleaved in vivo. The linkers are of use in forming prodrugs and conjugates of the cytotoxins of the invention as well as other diagnostic and therapeutic moieties. The invention provides prodrugs and conjugates of the duocarmycin analogues with the linker arms of the invention.Type: ApplicationFiled: March 4, 2009Publication date: August 20, 2009Applicant: Medarex, Inc.Inventors: Howard P. Ng, Danny P.C. McGee, Guoxian Wu, Jimmie Moore, Zhihong Li, Sanjeev Gangwar, Oliver L. Saunders, Irina Astafieva
-
Publication number: 20090202536Abstract: The present invention relates to antibody-drug conjugate compounds of Formula I: Ab-(L-D)p??I where one or more maytansinoid drug moieties (D) are covalently linked by L to an antibody (Ab) which binds to an ErbB receptor, or which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be used in methods of diagnosis or treatment of cancer, and other diseases and disorders.Type: ApplicationFiled: December 2, 2008Publication date: August 13, 2009Applicant: Genentech, Inc.Inventors: Allen J. Ebens, JR., Frederic S. Jacobson, Paul Polakis, Ralph H. Schwall, Mark X. Sliwkowski, Susan D. Spencer
-
Publication number: 20090191196Abstract: The invention describes the use of an antibody specific for serum amyloid P component, for the treatment or prophylaxis of amyloidosis, and the use of a compound which depletes serum amyloid P component from the circulation in combination with an antibody specific for serum amyloid P component.Type: ApplicationFiled: December 30, 2008Publication date: July 30, 2009Inventor: Mark B. Pepys
-
Publication number: 20090181039Abstract: A conjugate of an active agent and a targeting moiety having affinity for a target cell, in which the active agent has been modified by attachment of a cell membranes impermeabilizing group so that, if the active agent so modified is cleaved from the conjugate in the blood plasma instead of inside the target cell, the cell membrane-impermeabilizing group prevents or limits entry of the modified active agent into cells, thus reducing its systemic or non-specific adverse effects, including toxicity.Type: ApplicationFiled: March 20, 2009Publication date: July 16, 2009Inventors: Daniel V. Santi, Brian Hearn
-
Publication number: 20090117100Abstract: Cysteine engineered anti-TENB2 antibodies are engineered by replacing one or more amino acids of a parent anti-TENB2 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-TENB2 antibodies are provided. Cysteine engineered anti-TENB2 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-TENB2 antibody-drug conjugates having Formula I: Ab-(L-D)p??I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.Type: ApplicationFiled: October 16, 2008Publication date: May 7, 2009Inventors: Weiguang Mao, Jagath Reddy Junutula, Paul Polakis
-
Patent number: 7527787Abstract: The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Preferred embodiments concern hexameric stably tethered structures comprising one or more IgG antibody fragments and which may be monospecific or bispecific. The disclosed methods and compositions provide a facile and general way to obtain stably tethered structures of virtually any functionality and/or binding specificity. The stably tethered structures may be administered to subjects for diagnostic and/or therapeutic use, for example for treatment of cancer or autoimmune disease. The stably tethered structures may bind to and/or be conjugated to a variety of known effectors, such as drugs, enzymes, radionuclides, therapeutic agents and/or diagnostic agents.Type: GrantFiled: December 5, 2006Date of Patent: May 5, 2009Assignee: IBC Pharmaceuticals, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi
-
Publication number: 20090111756Abstract: Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) having a carboxylic acid equivalent at the C-terminal phenylalanine were prepared and attached to ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.Type: ApplicationFiled: July 7, 2006Publication date: April 30, 2009Applicant: Seattle Genectics, Inc.Inventors: Svetlana O. Doronina, Toni Beth Kline, Scott Jeffrey, Peter D. Senter, Damon Meyer
-
Publication number: 20090105461Abstract: Anti-Lewis Y antibodies are described. Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Specifically, monomeric calicheamicin derivative/anti-Lewis Y antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described.Type: ApplicationFiled: August 4, 2008Publication date: April 23, 2009Applicant: WyethInventors: Arthur Kunz, Justin Keith Moran, Joseph Thomas Rubino, Neera Jain, Erwin Raymond Arsene Boghaert, Philip Ross Hamann, Mark Edward Ruppen, Nitin Krishnaji Damle, Eugene Vidunas, Lyka Kalyandrug
-
Patent number: 7511094Abstract: The present invention is directed to alkanal derivatives of water-soluble polymers such as poly(ethylene glycol), their corresponding hydrates and acetals, and to methods for preparing and using such polymer alkanals. The polymer alkanals of the invention are prepared in high purity and exhibit storage stability.Type: GrantFiled: March 13, 2006Date of Patent: March 31, 2009Assignee: Nektar Therapeutics AL, CorporationInventor: Antoni Kozlowski
-
Publication number: 20090047296Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.Type: ApplicationFiled: August 3, 2007Publication date: February 19, 2009Applicant: Seattle Genetics, Inc.Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
-
Publication number: 20090041749Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.Type: ApplicationFiled: June 14, 2006Publication date: February 12, 2009Applicant: Genentech, Inc.Inventors: Mark S. Dennis, William Mallet, Paul Polakis
-
Publication number: 20090036431Abstract: The present invention is related to new tomaymycin derivatives, their process of preparation and their therapeutic uses.Type: ApplicationFiled: July 16, 2008Publication date: February 5, 2009Applicant: SANOFI-AVENTISInventors: Laurence GAUZY, Herve BOUCHARD, Ravi V.J. CHARI, Alain COMMERCON, Robert ZHAO, Yonghong DENG, Wei LI
-
Publication number: 20090004118Abstract: Disclosed herein are conjugates comprising a nanocarrier, a therapeutic agent or imaging agent and a targeting agent. Also disclosed herein are compositions comprising such conjugates and methods for using the conjugates to deliver therapeutic and/or imaging agents to cells. Also disclosed are methods for using the conjugates to treat particular disorders, such as proliferative disorders.Type: ApplicationFiled: October 7, 2005Publication date: January 1, 2009Inventors: Shuming Nie, Yong Kyu Lee, Gloria Kim
-
Publication number: 20080312422Abstract: A method is disclosed for preparing hydrazides from hydrazine and an acyl chloride which comprises the steps of (a) preparing a stirred substantially uniform slurry comprising hydrazine and an inert solvent at low temperature; and (b) adding an acyl chloride continuously to said slurry. The method avoids or limits production of undesired bis-hydrazide by-products. The method is used to prepare 3-methyl-3-mercaptobutanoic acid hydrazide, a molecule used to link calicheamicin to a monoclonal antibody.Type: ApplicationFiled: May 20, 2008Publication date: December 18, 2008Applicant: WyethInventors: George Anello Chiarello, Ayman Sahli
-
Publication number: 20080305037Abstract: An improved linker which lacks chiral centers between a hydrophobic anchor for coupling to lipid-based particles and a targeting agent has suitable hydrophobic/hydrophilic properties for use in vivo.Type: ApplicationFiled: October 16, 2007Publication date: December 11, 2008Inventor: William D. McGhee
-
Publication number: 20080260757Abstract: Drug compositions, fusions and conjugates are provided. The drug fusions and conjugates contain a therapeutic or diagnostic agent that is fused or conjugated to an antigen-binding fragment of an antibody that binds serum albumin. The drug compositions, fusions and conjugates have a longer in vivo half-life in comparison with the unconjugated or unfused therapeutic or diagnostic agent.Type: ApplicationFiled: May 31, 2005Publication date: October 23, 2008Inventors: Lucy J. Holt, Ian M. Tomlinson
-
Publication number: 20080248053Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.Type: ApplicationFiled: August 3, 2007Publication date: October 9, 2008Applicant: Seattle Genetics, Inc.Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
-
Publication number: 20080241128Abstract: Ligand Drug conjugate compounds comprising a ?-glucuronide-based linker and methods of using such compounds are provided.Type: ApplicationFiled: July 18, 2006Publication date: October 2, 2008Applicant: Seattle Genetics, Inc.Inventor: Scott Jeffrey
-
Publication number: 20080213289Abstract: The present invention relates to methods and compositions for the treatment of Hodgkin's Disease, comprising administering proteins characterized by their ability to bind to CD30, or compete with monoclonal antibodies AC10 or HeFi-1 for binding to CD30, and exert a cytostatic or cytotoxic effect on Hodgkin's disease cells in the absence of effector cells or complement. Such proteins include derivatives of monoclonal antibodies AC10 and HeFi-1. The proteins of the invention can be human, humanized, or chimeric antibodies; further, they can be conjugated to cytotoxic agents such as chemotherapeutic drugs. The invention further relates to nucleic acids encoding the proteins of the invention. The invention yet further relates to a method for identifying an anti-CD30 antibody useful for the treatment or prevention of Hodgkin's Disease.Type: ApplicationFiled: January 18, 2008Publication date: September 4, 2008Applicant: SEATTLE GENETICS, INC.Inventors: Joseph A. Francisco, Grant Risdon, Alan F. Wahl, Clay Siegall, Peter D. Senter, Svetlana Doronina, Brian E. Toki
-
Publication number: 20080193976Abstract: The present invention provides PE CD4+T-cell epitopes, as well as novel variants that exhibit reduced immunogenic responses, as compared to the parental PE. The present invention further provides DNA molecules that encode novel PE variants, host cells comprising DNA encoding novel PE variants, as well as methods for making PEs less immunogenic. In addition, the present invention provides various compositions that comprise these PE variants that are less immunogenic than wild-type PEs.Type: ApplicationFiled: September 12, 2006Publication date: August 14, 2008Inventor: Fiona A. Harding
-
Patent number: 7399644Abstract: An assay method for determining presence of a target antibody or antigen in a specimen qualitatively or quantitatively by mixing the specimen with an antigen or antibody immunologically reactive with the target antibody or antigen, and assaying the level of the immunological agglutination reaction, wherein the reactive antigen or antibody is effectively immobilized on the carrier via an amino acid sequence capable of binding to the carrier.Type: GrantFiled: June 4, 2003Date of Patent: July 15, 2008Assignee: Canon Kabushiki KaishaInventors: Tsutomu Honma, Tetsuya Yano, Tsuyoshi Nomoto, Shinya Kozaki
-
Publication number: 20080160020Abstract: The present invention relates to a method for inhibiting a disease response in a subject comprising contacting dead or dying cells exposing an antigen selected from the group consisting of a phosphorylcholine (PC) determinant, a phosphatidyl serine (PS) determinant, a MDA determinant, and cardiolipin in the subject, with an antibody or recombinant protein that recognizes and binds the antigen that is exposed on the dead or dying cells, thereby inhibiting the pathologic response in the subject.Type: ApplicationFiled: February 7, 2006Publication date: July 3, 2008Inventor: Gregg J. Silverman